Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Crossbow Therapeutics, Inc.

News headline image
Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies
From Crossbow Therapeutics, Inc.
Via Business Wire
News headline image
Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer
From Crossbow Therapeutics, Inc.
Via Business Wire
News headline image
Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies
From Crossbow Therapeutics, Inc.
Via Business Wire
News headline image
Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies
From Crossbow Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.